PTEN plasticity: How the taming of a lethal gene can go too far

Trends in Cell Biology

Volumn 23, Issue 8, 2013, Pages 374-379

  Naguib, Adam ^a   Trotman, Lloyd C ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

Nerve regeneration; PTEN regulation; Stroke; Tumour suppressor

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; PROTEIN KINASE B; UBIQUITIN PROTEIN LIGASE NEDD4;

CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVITY; HUMAN; ISCHEMIA; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; VASCULARIZATION; WOUND HEALING;

NERVE REGENERATION; PTEN REGULATION; STROKE; TUMOUR SUPPRESSOR;

CELL SURVIVAL; GENES, LETHAL; HUMANS; NEOPLASMS; NEURONS; PTEN PHOSPHOHYDROLASE; WOUND HEALING;

EID: 84880964865     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2013.03.003     Document Type: Review

References (69)

1. Li J., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
2. Steck P.A., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15:356-362.
3. Leslie N.R., Downes C.P. PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 2004, 382:1-11.
4. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 2004, 22:2954-2963.
5. Carracedo A., et al. PTEN level in tumor suppression: how much is too little?. Cancer Res. 2011, 71:629-633.
6. Chen Z., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
7. Song M.S., et al. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
8. Leslie N.R., Foti M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol. Sci. 2011, 32:131-140.
9. Poliseno L., et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci. Signal. 2010, 3:ra29.
10. Tay Y., et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011, 147:344-357.
11. Salmena L., et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 2011, 146:353-358.
12. Stambolic V., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
13. Keyes K.T., et al. Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1198-H1208.
14. Shi G.D., et al. PTEN deletion prevents ischemic brain injury by activating the mTOR signaling pathway. Biochem. Biophys. Res. Commun. 2011, 404:941-945.
15. Mocanu M.M., Yellon D.M. PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury?. Br. J. Pharmacol. 2007, 150:833-838.
16. Omori N., et al. Enhanced phosphorylation of PTEN in rat brain after transient middle cerebral artery occlusion. Brain Res. 2002, 954:317-322.
17. Lee S.M., et al. The protective effect of early hypothermia on PTEN phosphorylation correlates with free radical inhibition in rat stroke. J. Cereb. Blood Flow Metab. 2009, 29:1589-1600.
18. Maccario H., et al. PTEN is destabilized by phosphorylation on Thr366. Biochem. J. 2007, 405:439-444.
19. Miller S.J., et al. Direct identification of PTEN phosphorylation sites. FEBS Lett. 2002, 528:145-153.
20. Al-Khouri A.M., et al. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J. Biol. Chem. 2005, 280:35195-35202.
21. Birle D., et al. Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. J. Immunol. 2002, 169:286-291.
22. Tolkacheva T., et al. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 2001, 61:4985-4989.
23. Torres J., Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 2001, 276:993-998.
24. Vazquez F., Devreotes P. Regulation of PTEN function as a PIP3 gatekeeper through membrane interaction. Cell Cycle 2006, 5:1523-1527.
25. Wang X., et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007, 128:129-139.
26. Torres J., et al. Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J. Biol. Chem. 2003, 278:30652-30660.
27. Howitt J., et al. Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia. J. Cell Biol. 2012, 196:29-36.
28. Trotman L.C., et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007, 128:141-156.
29. Lackovic J., et al. Differential regulation of Nedd4 ubiquitin ligases and their adaptor protein Ndfip1 in a rat model of ischemic stroke. Exp. Neurol. 2012, 235:326-335.
30. Zheng X., et al. Effects of wortmannin on phosphorylation of PDK1, GSK3-beta, PTEN and expression of Skp2 mRNA after ischemia/reperfusion injury in the mouse kidney. Int. Urol. Nephrol. 2008, 40:185-192.
31. Perandones C., et al. Correlation between synaptogenesis and the PTEN phosphatase expression in dendrites during postnatal brain development. Brain Res. Mol. Brain Res. 2004, 128:8-19.
32. Cai Q.Y., et al. Differential expression of PTEN in normal adult rat brain and upregulation of PTEN and p-Akt in the ischemic cerebral cortex. Anat. Rec. 2009, 292:498-512.
33. Lachyankar M.B., et al. A role for nuclear PTEN in neuronal differentiation. J. Neurosci. 2000, 20:1404-1413.
34. Jaworski J., et al. Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J. Neurosci. 2005, 25:11300-11312.
35. Ning K., et al. PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons. Hum. Mol. Genet. 2010, 19:3159-3168.
36. Shi S.H., et al. Hippocampal neuronal polarity specified by spatially localized mPar3/mPar6 and PI 3-kinase activity. Cell 2003, 112:63-75.
37. Li P.P., Peng H.B. Regulation of axonal growth and neuromuscular junction formation by neuronal phosphatase and tensin homologue signaling. Mol. Biol. Cell 2012, 23:4109-4117.
38. Drinjakovic J., et al. E3 ligase Nedd4 promotes axon branching by downregulating PTEN. Neuron 2010, 65:341-357.
39. DiAntonio A. Nedd4 branches out. Neuron 2010, 65:293-294.
40. Le T.T., et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 2005, 14:845-857.
41. Park K.K., et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 2008, 322:963-966.
42. Sun F., et al. Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature 2011, 480:372-375.
43. Ferguson T.A., Son Y.J. Extrinsic and intrinsic determinants of nerve regeneration. J. Tissue Eng. 2011, 2. 2041731411418392.
44. Christie K.J., et al. Disruption of E3 ligase NEDD4 in peripheral neurons interrupts axon outgrowth: linkage to PTEN. Mol. Cell. Neurosci. 2012, 50:179-192.
45. Kwak Y.D., et al. Functional interaction of phosphatase and tensin homologue (PTEN) with the E3 ligase NEDD4-1 during neuronal response to zinc. J. Biol. Chem. 2010, 285:9847-9857.
46. Maddika S., et al. WWP2 is an E3 ubiquitin ligase for PTEN. Nat. Cell Biol. 2011, 13:728-733.
47. Van Themsche C., et al. X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J. Biol. Chem. 2009, 284:20462-20466.
48. Kawabe H., et al. Regulation of Rap2A by the ubiquitin ligase Nedd4-1 controls neurite development. Neuron 2010, 65:358-372.
49. Kwon C.H., et al. Pten regulates neuronal arborization and social interaction in mice. Neuron 2006, 50:377-388.
50. Chen M., et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011, 20:173-186.
51. Day N., et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br. J. Cancer 1999, 80(Suppl. 1):95-103.
52. Naguib A., et al. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer 2011, 11:123.
53. Kim S.S., et al. Expression of NEDD4-1, a PTEN regulator, in gastric and colorectal carcinomas. APMIS 2008, 116:779-784.
54. Yanagawa N., et al. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J. Thorac. Oncol. 2012, 7:1513-1521.
55. Amodio N., et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am. J. Pathol. 2010, 177:2622-2634.
56. Gimm O., et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am. J. Pathol. 2000, 156:1693-1700.
57. Perren A., et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 2000, 157:1097-1103.
58. Whiteman D.C., et al. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int. J. Cancer 2002, 99:63-67.
59. Trotman L.C., et al. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006, 441:523-527.
60. Xiong Q., et al. PTEN regulation of local and long-range connections in mouse auditory cortex. J. Neurosci. 2012, 32:1643-1652.
61. Nagata Y., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
62. Frattini M., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 2007, 97:1139-1145.
63. Keniry M., Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008, 27:5477-5485.
64. Vu B.T., Vassilev L. Small-molecule inhibitors of the p53-MDM2 interaction. Curr. Top. Microbiol. Immunol. 2011, 348:151-172.
65. Wade M., et al. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 2013, 13:83-96.
66. Schmid A.C., et al. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 2004, 566:35-58.
67. Hobert J.A., Eng C. PTEN hamartoma tumor syndrome: an overview. Genet. Med. 2009, 11:687-694.
68. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U.S.A. 1971, 68:820-823.
69. Berger A.H., et al. A continuum model for tumour suppression. Nature 2011, 476:163-169.